Afatinib | BIBW 2992 | Tyrosine / EGF Receptor Protein Kinase Inhibitor | EGFR | HER2

Afatinib/阿法替尼 {[allProObj[0].p_purity_real_show]}

货号：A149039 同义名： BIBW 2992

Afatinib（BIBW 2992）是一种口服活性强且不可逆的ErbB家族（EGFR和HER2）双特异性抑制剂，对EGFRwt、EGFRL858R、EGFRL858R/T790M和HER2的IC50值分别为0.5 nM、0.4 nM、10 nM和14 nM。阿法替尼用于研究食管鳞状细胞癌（ESCC）、非小细胞肺癌（NSCLC）和胃癌。

Afatinib/阿法替尼化学结构
CAS号：850140-72-6

Afatinib/阿法替尼 3D分子结构
CAS号：850140-72-6

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]}	现货	1周咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

EGFR 亚型比较

HER2 亚型比较

产品名称	EGFR/ErbB1 ↓ ↑	ErbB3 ↓ ↑	ErbB4 ↓ ↑	HER2/ErbB2 ↓ ↑	mutant EGFR ↓ ↑	其他靶点	纯度
WZ-3146	++++ EGFR (E746_A750/T790M), IC50: 14 nM EGFR (E746_A750), IC50: 2 nM						99%+
Daphnetin	+ EGFR, IC50: 7.67 μM					PKA,PKC	95%
Lifirafenib	++ EGFR, IC50: 29 nM				+ EGFR(T790M/L858R), IC50: 495 nM		98%
PD168393	++++ EGFR, IC50: 0.70 nM						99%+
Nazartinib	++ mutant EGFR, Ki: 0.031 μM				++ mutant EGFR, Ki: 0.031 μM		98%
Norcantharidin	✔						98%
CL-387785	++++ EGFR, IC50: 370 pM						98%
WHI-P154	+++ EGFR, IC50: 4 nM					Src,VEGFR	98%
Tyrphostin A9	+ EGFR, IC50: 460 μM					PDGFR	98%
AG 555	+ EGFR, IC50: 0.7 μM						98%
AG 494	+ EGFR, IC50: 1.2 μM						99%+
AG-556	+ EGFR, IC50: 5 μM						98%
RG13022	+ EGFR, IC50: 4 μM						99%+
Tyrphostin RG 14620	✔						99%+
Vandetanib	+ EGFR, IC50: 500 nM						99%
CNX-2006	++ mutant EGFR, IC50: <20 nM				++ mutant EGFR, IC50: <20 nM		99%
AZD3759	++++ EGFR (WT), IC50: 0.3 nM EGFR (L858R), IC50: 0.2 nM						98%
Erlotinib	++++ EGFR, IC50: 2 nM						95%
Saracatinib	+++ EGFR, IC50: 5 nM EGFR (L861Q), IC50: 4 nM						99%+
AG1557	✔						99%
Rociletinib	++ EGFR (wt), Ki: 303.3 nM EGFR (L858R/T790M), Ki: 21.5 nM						98%
AG490	+ EGFR, IC50: 0.1 μM						98%
Cetuximab	++++ EGFR, Kd: 0.39 nM						95%
Osimertinib	++ L858R/T790M EGFR, IC50: 11.44 nM WT EGFR, IC50: 12.92 nM						98%
Osimertinib mesylate	✔						98% (Content MsOH 15.2-18.2%)
Chrysophanol	✔					mTOR	98%
PD153035	++++ EGFR, Ki: 5.2 pM						99%+
Olmutinib	✔					BTK	99%+
WZ4002	++++ EGFR (L858R), IC50: 2 nM EGFR (L858R/T790M), IC50: 8 nM						99%+
Icotinib	+++ EGFR, IC50: 5 nM						99%
Desmethyl Erlotinib HCl	++++ EGFR, IC50: 2 nM						98%
Cyasterone	✔						99%+
PP 3	+ EGFR tyrosine kinase, IC50: 2.7 μM						98%
WZ8040	✔						99%+
(-)-Epigallocatechin Gallate	✔						99%
AG 18	+ EGFR, IC50: 35 μM						99%+
O-Desmethyl gefitinib	++ EGFR, IC50: 36 nM						99%
Falnidamol	✔						99%+
AZ-5104	++++ EGFR (L858R), IC50: 6 nM EGFR (L861Q) , IC50: <1 nM		+++ ErbB4, IC50: 7 nM			BRK	99%+
Butein	✔						95%
Genistein	✔						98%
SU5214	+ EGFR, IC50: 36.7 μM						99%+
Naquotinib	✔						99%+
Gefitinib	++ EGFR, IC50: 15.5 nM				+ EGFR (858R/T790M), IC50: 823.3 nM		98%
Theliatinib	+++ WT EGFR, IC50: 3 nM				++ EGFR T790M/L858R, IC50: 22 nM		99%
Lazertinib	++++ L858R/T790M EGFR, IC50: 2 nM WT EGFR, IC50: 76 nM				++++ Del19/T790M, IC50: 1.7 nM		99%+
Gefitinib-based PROTAC 3	++ EGFR, DC50: 22.3 nM						99%+
MTX-211	✔					PI3K	98%
(E)-AG 99	✔						99%+
Licochalcone D	✔					Caspase,PARP	99%
Zipalertinib	+++ EGFR WT, IC50: 8 nM EGFR (L861Q), IC50: 4.1 nM		+++ HER4, IC50: 4 nM		++++ EGFR L858R, IC50: 2 nM EGFR(d746-750), IC50: 1.4 nM		97%
JND3229	+++ EGFR WT, IC50: 6.8 nM				++ EGFR L858R/T790M, IC50: 30.5 nM		99%+
Firmonertinib mesylate	✔						99%+
Tyrphostin AG30	✔						99%+
EGFR-IN-12	++ EGFR, IC50: 21 nM						99%+
Mobocertinib	✔						98%
(Rac)-JBJ-04-125-02	✔						95%
(S)-Sunvozertinib	✔						99%
BLU-945	✔						95%
Poziotinib	+++ HER1, IC50: 3.2 nM		++ HER4, IC50: 23.5 nM	+++ HER2, IC50: 5.3 nM			98%
TAK-285	++ EGFR/HER1, IC50: 23 nM		+ HER4, IC50: 260 nM	++ HER2, IC50: 17 nM			99%+
ARRY-380 analog				✔			99%
Canertinib	++++ EGFR, IC50: 1.5 nM			+++ ErbB2, IC50: 9.0 nM			99%+
Dacomitinib	+++ EGFR, IC50: 6.0 nM		+ ErbB4, IC50: 73.7 nM	+ ErbB2, IC50: 45.7 nM			98%
EGFR/ErbB-2/ErbB-4 inhibitor-2			+ ErbB4, IC50: 1.91 μM	+ ErbB2, IC50: 0.08 μM			99%+
(E/Z)-CP-724714				++ HER2/ErbB2, IC50: 10 nM			95%
Lapatinib	++ EGFR, IC50: 10.8 nM		+ ErbB4, IC50: 367 nM	+++ ErbB2, IC50: 9.2 nM			98%
AEE788	++++ EGFR, IC50: 2 nM		+ HER4/ErbB4, IC50: 160 nM	+++ HER2/ErbB2, IC50: 6 nM		c-Fms/CSF1R	98+%
AV-412 free base	++++ EGFR, IC50: 0.75 nM			++ ErbB2, IC50: 19 nM	++++ EGFR^T790M, IC50: 0.79 nM EGFR^L858R/T790M, IC50: 0.51 nM		98+%
Neratinib	+ EGFR, IC50: 92 nM			+ HER2, IC50: 59 nM		Src	98%
BMS-599626	++ HER1, IC50: 20 nM		+ HER4, IC50: 190 nM	++ HER2, IC50: 30 nM			98%
Tucatinib				+++ ErbB2, IC50: 8 nM			98%
Allitinib	++++ EGFR, IC50: 0.5 nM		++++ ErbB4, IC50: 0.8 nM	+++ ErbB2, IC50: 3.0 nM			99%
Pelitinib	+ EGFR, IC50: 38.5 nM			+ ErbB2, IC50: 1.255 μM		Src,Raf	99%+
Sapitinib	+++ EGFR, IC50: 4 nM	+++ ErbB3, IC50: 4 nM		+++ ErbB2, IC50: 3 nM			99%+
CUDC-101	+++ EGFR, IC50: 2.4 nM			++ HER2, IC50: 15.7 nM		HDAC	99%+
Varlitinib	+++ ErbB1, IC50: 7 nM			++++ ErbB2, IC50: 2 nM			99%+
Afatinib dimaleate	++++ EGFR (wt), IC50: 0.5 nM EGFR (L858R/T790M), IC50: 0.4 nM			++ HER2, IC50: 14 nM			98%
Canertinib 2HCl	+++ EGFR, IC50: 7.4 nM			+++ ErbB2, IC50: 9 nM			99%
Allitinib tosylate	++++ EGFR, IC50: 0.5 nM EGFR (T790M/L858R), IC50: 12 nM		++++ ErbB4, IC50: 0.8 nM	+++ ErbB2, IC50: 3.0 nM			99%
Tyrphostin AG 528	+ EGFR, IC50: 4.9 μM			+ HER2, IC50: 2.1 μM			97%
Afatinib	++++ EGFR (wt), IC50: 0.5 nM EGFR (L858R), IC50: 10 nM		++++ ErbB4, IC50: 1 nM	++ HER2, IC50: 14 nM			99%
Pyrotinib dimaleate	++ EGFR, IC50: 0.013 μM			++ HER2, IC50: 0.038 μM			98%
Epertinib HCl	++++ EGFR, IC50: 1.48 nM		+++ HER4, IC50: 2.49 nM	+++ HER2, IC50: 7.15 nM			99%
Tuxobertinib	++++ EGFR, Kd: 0.2 nM			++++ HER2, Kd: 0.76 nM			99%
ALK-IN-1					++ EGFR(del19), IC50: 36.8 nM EGFR(C797S/del19), IC50: 138.6 nM	ALK	99%
Brigatinib					+ EGFR(C797S/T790M/del19), IC50: 67.2 nM EGFR(del19), IC50: 39.9 nM	FLT3,ALK	98%
Avitinib					++++ EGFR L858R/T790M, IC50: 0.18 nM	BTK	99%+
EAI045					✔		97%
Almonertinib					✔		99%
BI-4020					++++ EGFR^{del19 T790M C797S}, IC50: 0.2 nM		99%+
EGFR-IN-7					++++ EGFR^L858R/T790M, IC50: 0.19 nM EGFR^{d746-750/T790M/C797S}, IC50: 0.26 nM		99%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	HER2 ↓ ↑	其他靶点	纯度
Poziotinib	++++ HER2, IC50: 5.3 nM		98%
Tyrphostin AG 879	+ HER2-Neu, IC50: 1.0 μM		95%
TAK-285	+ HER2, IC50: 17 nM		99%+
ARRY-380 analog	✔		99%
Canertinib	+++ ErbB2, IC50: 9.0 nM	EGFR	99%+
(E/Z)-CP-724714	++ HER2/ErbB2, IC50: 10 nM		95%
Lapatinib	+++ ErbB2, IC50: 9.2 nM	EGFR	98%
AEE788	++++ HER2/ErbB2, IC50: 6 nM	EGFR	98+%
Neratinib	+ HER2, IC50: 59 nM	Src,EGFR	98%
BMS-599626	+ HER2, IC50: 30 nM		98%
Mubritinib	++++ HER2/ErbB2, IC50: 6.0 nM		99%+
Tucatinib	+++ ErbB2, IC50: 8 nM		98%
Sapitinib	++++ ErbB2, IC50: 3 nM	EGFR	99%+
CUDC-101	++ HER2, IC50: 15.7 nM	EGFR,HDAC	99%+
Afatinib dimaleate	++ HER2, IC50: 14 nM		98%
Afatinib	++ HER2, IC50: 14 nM		99%
Pertuzumab	✔		95%
Trastuzumab	✔		99%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Afatinib/阿法替尼生物活性

靶点

EGFR/ErbB1

EGFR (wt), IC50:0.5 nM

EGFR (L858R), IC50:10 nM
HER2/ErbB2

HER2, IC50:14 nM
ErbB4

ErbB4, IC50:1 nM
HER2

HER2, IC50:14 nM

描述

Afatinib E-isomer is an irreversible, dual EGFR/HER2 inhibitor, shows potent activity against wild-type and mutant forms of EGFR and HER2, with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR wt, EGFR L858R, EGFR L858R/T790M and HER2, respectively.

Afatinib/阿法替尼细胞实验

Cell Line ICC10-6 ICC21 MKN7 MKN1 NCI-N87 Cos-7 cells HCC1937 and HDQP1 cells TNBC cell lines human cardiac microvascular ECs	Concentration	Treated Time	Description	References
ICC10-6	100 nM	10 days	To evaluate the effect of Afatinib alone or in combination with infigratinib on the viability of ICC10-6 cells	Cancer Discov. 2022 May 2;12(5):1378-1395.
ICC21	100 nM	7 days	To evaluate the effect of Afatinib alone or in combination with infigratinib on the viability of ICC21 cells	Cancer Discov. 2022 May 2;12(5):1378-1395.
MKN7	0.5 µM	20 min	To study the effect of Afatinib on EGFR and HER2 in MKN7 cells. Results showed that Afatinib slightly reduced the phosphorylation of EGFR and HER2.	Mol Oncol. 2018 Apr;12(4):441-462.
MKN1	0.5 µM	20 min	To study the effect of Afatinib on EGFR in MKN1 cells. Results showed that Afatinib reduced the phosphorylation of EGFR.	Mol Oncol. 2018 Apr;12(4):441-462.
NCI-N87	0.5 µM	20 min	To study the effect of Afatinib on HER family RTKs in NCI-N87 cells. Results showed that Afatinib alone or in combination with trastuzumab significantly reduced the phosphorylation of EGFR and HER3.	Mol Oncol. 2018 Apr;12(4):441-462.
Cos-7 cells	10 nM	two weeks	To screen for cell clones carrying EGFR Exon 20 insertion mutations	Mol Cancer Ther. 2018 May;17(5):885-896.
HCC1937 and HDQP1 cells	1 µM	5 days	To evaluate the effect of afatinib in combination with other targeted therapies, the combination of afatinib and dasatinib showed the greatest growth inhibition in HCC1937 and HDQP1 cells.	Ther Adv Med Oncol. 2020 Jan 28;12:1758835919897546.
TNBC cell lines	0.008 to 5.0 µM	5 days	To assess the single-agent antiproliferative effects of afatinib, we tested the effect of afatinib on a panel of 14 TNBC cell lines, showing varying IC50 values.	Ther Adv Med Oncol. 2020 Jan 28;12:1758835919897546.
human cardiac microvascular ECs	50 ng/mL	1, 3, or 6 h	To study the effect of VEGF treatment on Nrg1-β1 concentration	Circulation. 2019 May 28;139(22):2570-2584.

Cell Line

ICC10-6 ICC21 MKN7 MKN1 NCI-N87 Cos-7 cells HCC1937 and HDQP1 cells TNBC cell lines human cardiac microvascular ECs

Concentration

Treated Time

Description

References

ICC10-6

100 nM

10 days

To evaluate the effect of Afatinib alone or in combination with infigratinib on the viability of ICC10-6 cells

Cancer Discov. 2022 May 2;12(5):1378-1395.

ICC21

100 nM

7 days

To evaluate the effect of Afatinib alone or in combination with infigratinib on the viability of ICC21 cells

Cancer Discov. 2022 May 2;12(5):1378-1395.

MKN7

0.5 µM

20 min

To study the effect of Afatinib on EGFR and HER2 in MKN7 cells. Results showed that Afatinib slightly reduced the phosphorylation of EGFR and HER2.

Mol Oncol. 2018 Apr;12(4):441-462.

MKN1

0.5 µM

20 min

To study the effect of Afatinib on EGFR in MKN1 cells. Results showed that Afatinib reduced the phosphorylation of EGFR.

Mol Oncol. 2018 Apr;12(4):441-462.

NCI-N87

0.5 µM

20 min

To study the effect of Afatinib on HER family RTKs in NCI-N87 cells. Results showed that Afatinib alone or in combination with trastuzumab significantly reduced the phosphorylation of EGFR and HER3.

Mol Oncol. 2018 Apr;12(4):441-462.

Cos-7 cells

10 nM

two weeks

To screen for cell clones carrying EGFR Exon 20 insertion mutations

Mol Cancer Ther. 2018 May;17(5):885-896.

HCC1937 and HDQP1 cells

1 µM

5 days

To evaluate the effect of afatinib in combination with other targeted therapies, the combination of afatinib and dasatinib showed the greatest growth inhibition in HCC1937 and HDQP1 cells.

Ther Adv Med Oncol. 2020 Jan 28;12:1758835919897546.

TNBC cell lines

0.008 to 5.0 µM

5 days

To assess the single-agent antiproliferative effects of afatinib, we tested the effect of afatinib on a panel of 14 TNBC cell lines, showing varying IC50 values.

Ther Adv Med Oncol. 2020 Jan 28;12:1758835919897546.

human cardiac microvascular ECs

50 ng/mL

1, 3, or 6 h

To study the effect of VEGF treatment on Nrg1-β1 concentration

Circulation. 2019 May 28;139(22):2570-2584.

Afatinib/阿法替尼动物实验

Species Mice Mice CB17 SCID mice CB17/lcr-Prkdc SCID/Crl mice Mice Mice	Animal Model ICC21 subcutaneous xenograft model Xenograft model H2073-SVD and H2073-ASV xenograft models HCC1806 xenograft model Non-small cell lung cancer patient-derived xenograft models C57BL/6J wild-type mice	Administration	Dosage	Frequency	Description	References
Mice	ICC21 subcutaneous xenograft model	Oral	15 mg/kg	Once daily for 21 days	To evaluate the anti-tumor effect of Afatinib alone or in combination with infigratinib in the ICC21 subcutaneous xenograft model	Cancer Discov. 2022 May 2;12(5):1378-1395.
Mice	Xenograft model	Subcutaneous injection	20 mg/kg	Once daily for 14 days	The combination treatment significantly slowed tumor growth rate and reduced Ki67 expression, inducing DNA damage	Cell Death Dis. 2019 Sep 10;10(9):663.
CB17 SCID mice	H2073-SVD and H2073-ASV xenograft models	Oral	7.5 or 20 mg/kg	Once daily for 14 days	To evaluate the anti-tumor activity of Afatinib in xenograft models carrying EGFR Exon 20 insertion mutations, showing poor efficacy in these models	Mol Cancer Ther. 2018 May;17(5):885-896.
CB17/lcr-Prkdc SCID/Crl mice	HCC1806 xenograft model	Oral gavage	10 mg/kg	Once daily for 5 days, followed by 2 days off	To evaluate the antitumour efficacy of combining afatinib and dasatinib in the HCC1806 xenograft model, the combination treatment significantly inhibited tumour growth.	Ther Adv Med Oncol. 2020 Jan 28;12:1758835919897546.
Mice	Non-small cell lung cancer patient-derived xenograft models	Oral	15 mg/kg	5 days on, 2 days off, for 4 cycles	Afatinib, in combination with other drugs, completely suppressed tumor growth, showing significant anti-tumor effects.	Commun Biol. 2022 Jan 17;5(1):59
Mice	C57BL/6J wild-type mice	Oral gavage	25 mg/kg	For 2 weeks	To study the effect of ErbB signaling inhibition on VEGF-B-induced cardiac hypertrophy	Circulation. 2019 May 28;139(22):2570-2584.

Species

Mice Mice CB17 SCID mice CB17/lcr-Prkdc SCID/Crl mice Mice Mice

Animal Model

ICC21 subcutaneous xenograft model Xenograft model H2073-SVD and H2073-ASV xenograft models HCC1806 xenograft model Non-small cell lung cancer patient-derived xenograft models C57BL/6J wild-type mice

Administration

Dosage

Frequency

Description

References

Mice

ICC21 subcutaneous xenograft model

Oral

15 mg/kg

Once daily for 21 days

To evaluate the anti-tumor effect of Afatinib alone or in combination with infigratinib in the ICC21 subcutaneous xenograft model

Cancer Discov. 2022 May 2;12(5):1378-1395.

Mice

Xenograft model

Subcutaneous injection

20 mg/kg

Once daily for 14 days

The combination treatment significantly slowed tumor growth rate and reduced Ki67 expression, inducing DNA damage

Cell Death Dis. 2019 Sep 10;10(9):663.

CB17 SCID mice

H2073-SVD and H2073-ASV xenograft models

Oral

7.5 or 20 mg/kg

Once daily for 14 days

To evaluate the anti-tumor activity of Afatinib in xenograft models carrying EGFR Exon 20 insertion mutations, showing poor efficacy in these models

Mol Cancer Ther. 2018 May;17(5):885-896.

CB17/lcr-Prkdc SCID/Crl mice

HCC1806 xenograft model

Oral gavage

10 mg/kg

Once daily for 5 days, followed by 2 days off

To evaluate the antitumour efficacy of combining afatinib and dasatinib in the HCC1806 xenograft model, the combination treatment significantly inhibited tumour growth.

Ther Adv Med Oncol. 2020 Jan 28;12:1758835919897546.

Mice

Non-small cell lung cancer patient-derived xenograft models

Oral

15 mg/kg

5 days on, 2 days off, for 4 cycles

Afatinib, in combination with other drugs, completely suppressed tumor growth, showing significant anti-tumor effects.

Commun Biol. 2022 Jan 17;5(1):59

Mice

C57BL/6J wild-type mice

Oral gavage

25 mg/kg

For 2 weeks

To study the effect of ErbB signaling inhibition on VEGF-B-induced cardiac hypertrophy

Circulation. 2019 May 28;139(22):2570-2584.

Afatinib/阿法替尼参考文献

Afatinib/阿法替尼实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.06mL

0.41mL

0.21mL

10.29mL

2.06mL

1.03mL

20.58mL

4.12mL

2.06mL

Afatinib/阿法替尼技术信息

CAS号	850140-72-6
分子式	C₂₄H₂₅ClFN₅O₃
分子量	485.94
SMILES Code	O=C(NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1O[C@@H]4COCC4)/C=C/CN(C)C
MDL No.	MFCD12407405

别名	BIBW 2992
运输	蓝冰
InChI Key	ULXXDDBFHOBEHA-CWDCEQMOSA-N
Pubchem ID	10184653

存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Keep in dark place, sealed in dry, store in freezer, under -20°C

溶解方案

细胞实验：

DMSO: 105 mg/mL(216.08 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验：请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

方案二

方案三

配制的工作液建议现用现配，短期内尽快用完。以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

方案一

靶点

靶点	数值

EGFR/ErbB1	EGFR (wt), IC50:0.5 nM EGFR (L858R), IC50:10 nM
HER2/ErbB2	HER2, IC50:14 nM
ErbB4	ErbB4, IC50:1 nM
HER2	HER2, IC50:14 nM

Afatinib/阿法替尼 {[allProObj[0].p_purity_real_show]}

Afatinib/阿法替尼纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Afatinib/阿法替尼质控信息

Afatinib/阿法替尼生物活性

Afatinib/阿法替尼细胞实验

Afatinib/阿法替尼动物实验

Afatinib/阿法替尼参考文献

Afatinib/阿法替尼实验方案

Afatinib/阿法替尼技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Afatinib/阿法替尼 {[allProObj[0].p_purity_real_show]}

Afatinib/阿法替尼 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Afatinib/阿法替尼 质控信息

Afatinib/阿法替尼 生物活性

Afatinib/阿法替尼 细胞实验

Afatinib/阿法替尼 动物实验

Afatinib/阿法替尼 参考文献

Afatinib/阿法替尼 实验方案

Afatinib/阿法替尼 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Afatinib/阿法替尼纯度/质量文件产品仅供科研

Afatinib/阿法替尼质控信息

Afatinib/阿法替尼生物活性

Afatinib/阿法替尼细胞实验

Afatinib/阿法替尼动物实验

Afatinib/阿法替尼参考文献

Afatinib/阿法替尼实验方案

Afatinib/阿法替尼技术信息